# Study to Evaluate Efficacy and Safety of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Sickle Cell Disease (SCD)

> **NCT03055234** · PHASE3 · WITHDRAWN · sponsor: **United Therapeutics**

## Conditions studied

- Pulmonary Hypertension Associated With Sickle Cell Disease

## Interventions

- **DRUG:** Oral Treprostinil
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03055234
- **Lead sponsor:** United Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-06
- **Primary completion:** 2021-12
- **Final completion:** 2022-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Business decision
- **Last updated:** 2017-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03055234

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03055234, "Study to Evaluate Efficacy and Safety of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Sickle Cell Disease (SCD)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03055234. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*